Atogepant for Migraine Prevention: Benefits, Dosage, and Safety

Overview

The type of headache, which is commonly known as migraine, generates persistent pulsating head pain that usually appears on a single side. The headache episode commonly and mostly brings nausea along with vomiting and sensitivity to both sound and light. The headache persists for several hours up to multiple days. The 37 amino acid neuropeptide known as calcitonin gene-related peptide (CGRP), which has been discovered via research and study in molecular biology and neuroscience, is crucial to the pathophysiology of migraine. CGRP receptor antagonist is also known as Gepant. It is an oral medication that impedes the CGRP-related nociceptor signaling pathway. To date, three Gepants have been approved by the FDA (Food and Drug Administration) for migraine treatment.

Atogepant is a second-generation Gepant that antagonizes CGRP receptors, inhibiting neurogenic inflammation and pain sensitization. On September 28, 2021, the United States Food and Drug Administration approved Atogepant. It is the first medication of its class to be approved principally for the treatment of migraine. In addition, it has a long half-life and negligible cardiovascular or liver toxicity.

How Does Atogepant Work?

Calcitonin gene-related peptide (CGRP) has many bodily functions and nociceptive processes.

CGRP is found in two forms - alpha CGRP and beta CGRP.

Alpha CGRP is located within the main sensory neurons in the dorsal root ganglia and trigeminal system that are engaged in the pathogenesis of migraine headaches. The CGRP receptor consists of a G-protein-coupled receptor (GPCR), a calcitonin receptor-like receptor (CLR), and an additional protein receptor activity-modifying protein 1 (RAMP1). On activation, adenylyl cyclase catalyzes the formation of cAMP and other intracellular messengers. Atogepant is a second-generation oral CGRP receptor with a time-to-peak concentration or Tmax of around two and a half hours and a half-life of eleven hours. It is a dynamic CGRP antagonist that non-competitively binds to the CGRP receptors. Unlike other Gepants, Atogepants were developed explicitly to prevent migraines because of their long half-life. It works by obstructing the calcitonin gene-related peptide.

Who Can Use the Drug Atogepant?

A person with migraine can use Atogepant as it blocks calcitonin gene-related peptides.

Limitations

Physicians need to employ Atogepant with care in people who have end-stage kidney disease combined with serious liver disease.

Dosage and Administration Guidelines

• Route of Administration: Oral.

• Dosage Strengths: The drug comes in three strengths: 10 mg, 30 mg, and 60 mg.

• Dosage Forms: It is a white to off-white, oval-shaped biconvex tablet engraved with A30 on one side.

The physician would prescribe the smallest starting dose, which is recommended once a day, with or without food.

For Patients

What Is Atogepant?

Atogepant is a medicine that is used to prevent episodic migraine headaches. It is a class of medication known as calcitonin gene-related peptide receptor antagonists. Our body has a protein known as calcitonin gene-related peptide (CGRP), which is thought to cause migraine headaches. Atogepant blocks the action of calcitonin gene-related peptides, thus preventing migraine attacks.

How to Administer Atogepant?

• Atogepant comes in three strengths: 10 mg, 30 mg, and 60 mg.

• It should be taken once a day.

• It should be taken orally.

• It can be taken with or without food.

• The medicine should be taken at the same time daily.

• Atogepant prevents headaches but does not cure them, so one should continue taking it.

• Do not stop the medicine without the doctor's consent, even after feeling well.

• In case of any side effects, inform the doctor.

What Should One Inform the Doctor About Before Beginning the Drug?

• If one is allergic to Atogepant, any of the medication's constituents, or any other medicines in general, the doctor should be informed.

• The doctor should be informed about any other medications, vitamins, or nutritional supplements that one is taking. The following drugs should be mentioned without fail: Carbamazepine, Clarithromycin, Cyclosporine, Efavirenz, Etravirine, Itraconazole, Ketoconazole, Phenytoin, and Rifampin.

• Inform the physician about the herbal products if one is taking them.

• The doctor should be informed if one has kidney or liver ailments or has had them in the past.

• The doctor should be aware of the patient’s pregnancy.

What Are the Side Effects of Atogepant?

The following are the side effects of Atogepant:

• Nausea.

• Constipation.

• Fatigue.

• Loss of weight.

• Loss of appetite.

• Allergic reactions like rash, itching, swelling, severe dizziness, and trouble breathing.

• Call the doctor as soon as one develops these reactions.

What Are the Dietary Restrictions to Consider While Taking Atogepant?

The doctor should be informed about eating grapefruit and drinking grapefruit juice while taking the medication.

What Should Be Done About Missing a Dose?

• If one forgets to take the prescribed dose, the medicine should be taken as soon as one remembers.

• If it is almost time to take the next dose, skipping the amount and continuing the regular dosing should be a priority.

• Take the next dose at the same time.

• Avoid taking two medicines at the same time to catch up.

How to Store Atogepant?

• Atogepant should be stored at room temperature, away from heat, sunlight, and moisture.

• The optimal temperature for storing the drugs is around 20 to 25 degrees Celsius.

• The medication should be kept away from kids and pets.

• Always lock the safety caps of the medicines to protect small kids from poisoning.

How to Dispose of Atogepant?

• The medicine should not be flushed down the toilet or poured into a drain.

• Once the medicine expires, discard it through a medicine take-back program. The local pharmacist should be notified about the take-back program.

• If the medicine take-back program is not readily available, then any other drug disposal option should be sought.

What Should Be Done in Case of Atogepant Overdose?

In case of an overdose, the doctor should be contacted immediately. In the event that the individual who overdosed on drugs collapsed, experienced a seizure, or experienced breathing difficulties, emergency services should be called right away.

What Are the Benefits of Atogepant for Migraine Prevention?

Clinical studies show that taking Atogepant helps patients reduce migraine occurrence in monthly cycles; thus, they can actively engage in daily routines without stress about sudden migraines. Atogepant is the treatment choice for migraine patients who have not responded to standard approaches because of its distinct preventive mechanism of blocking calcitonin gene-related peptide (CGRP).

What Are the Tips for Maximizing the Effectiveness of Atogepant?

• Patients take various approaches, together with their medication prescription, to boost Atogepant's effectiveness for migraine prevention.

• Using a normal daily schedule with adequate water intake, a balanced diet, and regular sleep patterns has significant benefits in migraine treatment.

• Monitoring migraine symptoms and their causes and drug evaluations through a journal enables patients and healthcare providers to pursue informed decisions regarding treatment adjustments.

• Additional migraine prevention occurs when patients combine Atogepant treatment with stress-reduction practices, including yoga, mindfulness, or exercise routines.

• The best outcome of the therapy emerges through strict adherence to prescribed dosage instructions and ongoing communication with healthcare professionals about adverse effects.

For Doctors:

Indications:

Atogepant functions as a medication that helps prevent attacks of episodic migraine.

What Is the Pharmacology of Atogepant?

• Mechanism of Action

The body utilizes calcitonin gene-related peptide (CGRP) to execute six different processes, including vascular, digestive, sensory, vestibular, hematopoietic, immunomodulatory, and nociceptive functions. The protein molecules belonging to calcitonin gene-related peptides exist in two distinct types, which are designated alpha CGRP and beta CGRP. The main sensory neurons in the dorsal root ganglia and trigeminal region contain alpha CGRP. The system is engaged in the pathogenesis of migraine headaches.

• Pharmacodynamics:

On activation of receptor activity-modifying protein 1 (RAMP1), which makes up the CGRP receptor, adenylyl cyclase catalyzes the formation of cAMP and other intracellular messengers. CGRP is a cerebral vasodilator and is thought to play an important role in migraine pathophysiology. The pants bind to the CGRP receptors, thus reversing CGRP-induced neurogenic inflammation and vasodilation. Antogepant is a second-generation CGRP receptor with a half-life of eleven hours. It non-competitively binds to the CGRP receptor.

• Pharmacokinetics

A phase one clinical study described that Atogepant could be tolerated in single doses as high as three hundred milligrams with no cardiovascular adverse effects such as prolonged QT/QTc.

No ALT elevation above 1.5 x upper limit of normal (ULN) has been reported.

1. Distribution: Protein Bound- 4.7 % (unbound).

2. The Volume of Distribution: 292 L.

3. Metabolism: Atogepant is primarily metabolized by CYP3A4. Atogepant and a glucuronide conjugate metabolite (M23) are the most widely circulating compounds in the plasma, approximately seventy-five percent and fifteen percent, respectively. Ten other metabolites have been found in the feces, representing less than ten percent of the administered dosage.

4. Elimination: Atogepant is eliminated through the metabolism of CYP3A4. Forty-two percent of the dose was found unchanged in the feces, and five percent of the unaltered drug was in the urine. Approximately eighty-one percent of the radioactivity was found in the feces and eight percent in the urine.

Drug Interactions

• Atogepant interacts with around one hundred and sixty-two drugs, of which seventy-five are major, two are moderate, and eighty-five are minor drug interactions. To list a few-

• Atogepant administered with Sumatriptan was found to be safe and well tolerated.

• Atogepant, administered with either Acetaminophen or Naproxen, was found to be safe.

• Multiple daily doses of Atogepant co-administered with a single dose of Ethinyl Estradiol and Levonorgestrel were safe and well tolerated in healthy women.

• Co-administration with strong or moderate CYP3A4 inducers such as Rifampin, Carbamazepine, Phenytoin, St. John's wort, Efavirenz, and Etravirine. The recommended Atogepant dosage is 30 or 60 mg once a day.

• Co-administration with OATP inhibitors such as Cyclosporine, the Atogepant dosage is 10 or 30 mg daily.

What Have Clinical Trials Proven With Regards to Atogepant?

Advance - A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study was carried out to assess oral Atogepant's effectiveness, safety, and tolerability for preventing migraine in participants with episodic migraine (ADVANCE).

• Atogepant 10 mg tablets were given once a day orally, and placebo-matched Atogepant tablets were given once a day orally for 12 weeks.

• Atogepant 30 mg tablet was given once a day orally for 12 weeks.

• Atogepant 60 mg tablet was given once a day orally for 12 weeks.

Results: Atogepant proved effective in all tested doses during the initial twelve-week double-blind treatment period, which started with the initial four weeks, through their significant ability to reduce mean MMDs at individual threshold levels.

Side Effects of Atogepant:

1. General Side Effects

• Nausea.

• Constipation.

• Fatigue.

• Gastrointestinal Side Effects

• Constipation.

• Metabolic Side Effects

• Reduced appetite.

• Weight loss

2. Hepatic Side Effects

Patients treated develop transaminase elevation that exceeds the upper limit of normal (ULN) by a factor of three or greater. The patients do not show any symptoms, and the drug-induced increase in transaminase lasts for eight weeks, followed by its resolution when they discontinue the medication.

3. Nervous System

• Fatigue.

• Drowsiness.

Precautions and Safety Considerations

• Pregnancy: There is no sustainable evidence to suggest the risk of drug usage in pregnant women. However, migraine might increase the risk of high blood pressure during pregnancy.

• Lactation: There is no evidence of the presence of Atogepant in milk, its effects on breastfed infants, or milk production.

• Renal Impairment: No dose adjustment is needed for mild to moderate kidney impairment. The lowest dose is recommended for severe and end-stage kidney disease. The medicine should be taken after dialysis for end-stage kidney disease patients undergoing intermittent dialysis.

• Hepatic Impairment: Treatment for hepatic impairment requires no dosage change during mild to moderate conditions. The medication should be completely avoided during severe hepatic impairment conditions.

• Pediatric Patients: There is no data regarding the safety profile and effectiveness of the drug for pediatric patients.

Key Takeaway From iCliniq

The new oral drug Atogepant serves as a preventive migraine medication that gives patients an active approach to decreasing their attack frequency and impact. This drug's success is mainly due to its specificity in dealing with target pathways, since the patient must work with healthcare providers for better treatment benefits and to improve their day-to-day quality of life.